1. Home
  2. ITRG vs MAIA Comparison

ITRG vs MAIA Comparison

Compare ITRG & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra Resources Corp.

ITRG

Integra Resources Corp.

HOLD

Current Price

$3.18

Market Cap

586.3M

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.41

Market Cap

86.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRG
MAIA
Founded
1997
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
586.3M
86.2M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
ITRG
MAIA
Price
$3.18
$1.41
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$5.13
N/A
AVG Volume (30 Days)
2.8M
766.1K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$67.34
N/A
Revenue Next Year
$25.89
N/A
P/E Ratio
$45.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.43
$0.87
52 Week High
$4.87
$3.19

Technical Indicators

Market Signals
Indicator
ITRG
MAIA
Relative Strength Index (RSI) 54.84 49.37
Support Level $2.60 $1.26
Resistance Level $3.31 $1.46
Average True Range (ATR) 0.17 0.10
MACD 0.07 0.03
Stochastic Oscillator 89.23 79.69

Price Performance

Historical Comparison
ITRG
MAIA

About ITRG Integra Resources Corp.

Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: